StockMacro
Menu

Medifast

$11.75 -10% in 6 monthsMarket cap $131.4M

MED on XNYS, Consumer Staples, Medifast, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue fell 30% in a year to $299.6M, but insiders bought $1.8M of shares.

  • BadLatest quarter revenue fell 19% to $72M from $89.4M
  • BadShort interest 12% of shares, rising 12% over two weeks

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

Industry
Miscellaneous food preparations & kindred products (Consumer Staples)
Employees
380
Website
medifastinc.com
Listed
NYSE, US
Last results
26 Oct 2026
Next results
expected around 16 Feb 2027 (an estimate: a year ago it reported on 17 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $72.0M, net loss $17.5M.
Quarter to 31 Dec 2021: revenue –, net income $34.0MQuarter to 31 Mar 2022: revenue $417.6M, net income $41.8MQuarter to 31 Mar 2022: revenue $417.6M, net income $41.8MQuarter to 30 Jun 2022: revenue $453.3M, net income $39.1MQuarter to 30 Jun 2022: revenue $453.3M, net income $39.1MQuarter to 30 Sep 2022: revenue $390.4M, net income $36.2MQuarter to 30 Sep 2022: revenue $390.4M, net income $36.2MQuarter to 31 Dec 2022: revenue –, net income $26.5MQuarter to 31 Mar 2023: revenue $349.0M, net income $40.0MQuarter to 31 Mar 2023: revenue $349.0M, net income $40.0MQuarter to 30 Jun 2023: revenue $296.2M, net income $30.3MQuarter to 30 Jun 2023: revenue $296.2M, net income $30.3MQuarter to 30 Sep 2023: revenue $235.9M, net income $23.1MQuarter to 30 Sep 2023: revenue $235.9M, net income $23.1MQuarter to 31 Dec 2023: revenue $191.0M, net income $6.0MQuarter to 31 Dec 2023: revenue $191.0M, net income $6.0MQuarter to 31 Mar 2024: revenue $174.7M, net income $8.3MQuarter to 31 Mar 2024: revenue $174.7M, net income $8.3MQuarter to 30 Jun 2024: revenue $168.6M, net income -$8.2MQuarter to 30 Jun 2024: revenue $168.6M, net income -$8.2MQuarter to 30 Sep 2024: revenue $140.2M, net income $1.1MQuarter to 30 Sep 2024: revenue $140.2M, net income $1.1MQuarter to 31 Dec 2024: revenue $119.0M, net income $801KQuarter to 31 Dec 2024: revenue $119.0M, net income $801KQuarter to 31 Mar 2025: revenue $115.7M, net income -$772KQuarter to 31 Mar 2025: revenue $115.7M, net income -$772KQuarter to 30 Jun 2025: revenue $105.6M, net income $2.5MQuarter to 30 Jun 2025: revenue $105.6M, net income $2.5MQuarter to 30 Sep 2025: revenue $89.4M, net income -$2.3MQuarter to 30 Sep 2025: revenue $89.4M, net income -$2.3MQuarter to 31 Dec 2025: revenue $75.1M, net income -$18.1MQuarter to 31 Dec 2025: revenue $75.1M, net income -$18.1MQuarter to 31 Mar 2026: revenue $76.0M, net income -$2.1MQuarter to 31 Mar 2026: revenue $76.0M, net income -$2.1MQuarter to 30 Jun 2026: revenue $76.4M, net income -$3.1MQuarter to 30 Jun 2026: revenue $76.4M, net income -$3.1MQuarter to 30 Sep 2026: revenue $72.0M, net income -$17.5MQuarter to 30 Sep 2026: revenue $72.0M, net income -$17.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $453.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$72.0M-$17.5M
30 Jun 2026$76.4M-$3.1M
31 Mar 2026$76.0M-$2.1M
31 Dec 2025$75.1M-$18.1M
30 Sep 2025$89.4M-$2.3M
30 Jun 2025$105.6M$2.5M
31 Mar 2025$115.7M-$772K
31 Dec 2024$119.0M$801K
30 Sep 2024$140.2M$1.1M
30 Jun 2024$168.6M-$8.2M
31 Mar 2024$174.7M$8.3M
31 Dec 2023$191.0M$6.0M
30 Sep 2023$235.9M$23.1M
30 Jun 2023$296.2M$30.3M
31 Mar 2023$349.0M$40.0M
31 Dec 2022–$26.5M
30 Sep 2022$390.4M$36.2M
30 Jun 2022$453.3M$39.1M
31 Mar 2022$417.6M$41.8M
31 Dec 2021–$34.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $299.6M $429.7M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -30% +3.1%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$40.9M $248K
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.69 $0.01
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 69.2% 72.4% 29.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -11.6% -1.3% 4.8%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -13.6% 0.1% 3.0%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -20.7% 7.5%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$3.9M $646K
CashCash, cash equivalents and short-term investments on the latest balance sheet. $172.5M $173.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$172.5M (net cash) -$173.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.60
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $16.12
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 20.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.44 0.96
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 1.4
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.73 1.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
MedifastMED (this company) $131.4Mloss0.44-30%-13.6%
CoffeeJVA $28.1M6.00.29+8.2%4.9%
Utz BrandsUTZ $1.3Bloss0.88+0.5%-2.7%
Suja LifeSUJA $138.9M––––
BRCBRCC $181.0Mloss0.41+12%-1.5%
Beyond MeatBYND $71.3M–0.28-13%125%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$1.6M

bought $1.8M, sold $226K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-13%

95 13F filers vs 109

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

70%

7.9M shares held by 13F filers (30 Sep 2026) of 11.2M outstanding (19 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

1.3M shares sold short (30 Oct 2026) of 11.2M outstanding (19 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.2

1.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+12%

1.2M shares sold short in the report before, 1.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

51%

51% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-19%

$72.0M vs $89.4M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-69%

$427K vs $1.4M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

16

16 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

16 articles in the last 7 days; its usual week has 2.

Price $11.75 on 20 Nov 2026, +13% over 12 months (12-month range $9.45 to $13.37)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $2.6M in the last 12 months (the 12 months before: $5K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $72.0M in the latest quarter, -19% on a year earlier.
Capital spending per quarter. Capital spending $427K in the latest quarter, -69% on a year earlier.
Institutional holders (13F filers). 95 13F filers reported holding it in the latest 13F quarter, -19% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Jun 20268-K and other filingsDirector or officer change
26 May 20268-K and other filingsDirector or officer change
20 Mar 20268-K and other filingsDirector or officer change
5 Jan 20268-K and other filingsDirector or officer change
5 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jun 20258-K and other filingsDirector or officer change
20 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Nov 20248-K and other filingsA major agreement ended
30 Jul 2024Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.8M (2024-07-15); 2.0x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.8M (2024-06-28); 1.9x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 3.5M vs usual 1.8M (2024-06-14); 2.2x the same period a year earlier
21 Jun 20248-K and other filingsDirector or officer change
21 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jun 2024Sharp changeShort interest spike: short interest spike, 3.4M vs usual 1.7M (2024-05-31); 2.2x the same period a year earlier
28 May 2024Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.7M (2024-05-15); 2.0x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 3.1M vs usual 1.7M (2024-04-30); 1.8x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.7M (2024-04-15); 1.9x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 2.7M vs usual 1.7M (2024-03-28); 1.7x the same period a year earlier
7 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 235.9M vs usual 392.3M (2023-09-30); 0.6x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 1.7M vs usual 674K (2023-04-28); 3.0x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 627K (2023-04-14); 3.0x the same period a year earlier
20 Apr 20238-K and other filingsDirector or officer change
20 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Apr 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 624K (2023-03-31); 2.4x the same period a year earlier
28 Mar 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 615K (2023-03-15); 2.5x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 615K (2023-02-28); 2.4x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 1.2M vs usual 615K (2023-02-15); 1.9x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 853K vs usual 607K (2023-01-31); 1.6x the same period a year earlier
30 Aug 2022Sharp changeShort interest spike: short interest spike, 891K vs usual 584K (2022-08-15); 2.4x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 891K vs usual 581K (2022-07-29); 2.2x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 945K vs usual 577K (2022-07-15); 2.4x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 890K vs usual 575K (2022-06-30); 2.7x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 989K vs usual 563K (2022-06-15); 3.1x the same period a year earlier
16 Jun 20228-K and other filingsDirector or officer change
16 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$200K published
Month from 1 Apr 2022: $178K published
Month from 1 May 2022: $137K published
Month from 1 Aug 2022: $557K published
Month from 1 Nov 2022: $65K published
Month from 1 Feb 2023: $72K published
Month from 1 Mar 2023: -$239K published
Month from 1 May 2023: $74K published
Month from 1 Aug 2023: -$3.4M published
Month from 1 Oct 2023: -$415K published
Month from 1 Nov 2023: $21K published
Month from 1 Mar 2024: -$160K published
Month from 1 Jun 2025: $5K published
Month from 1 Mar 2026: $179K published
Month from 1 May 2026: $63K published
Month from 1 Aug 2026: $1.4M published
Month from 1 Oct 2026: -$158K published
Month from 1 Nov 2026: $1.1M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Mar 2022: $417.6M, +23% on a year earlier; public on 3 May 2022
Quarter ended 30 Jun 2022: $453.3M, +15% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $390.4M, -5.6% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $349.0M, -16% on a year earlier; public on 2 May 2023
Quarter ended 30 Jun 2023: $296.2M, -35% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $235.9M, -40% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $191.0M; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $174.7M, -50% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $168.6M, -43% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $140.2M, -41% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $119.0M, -38% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $115.7M, -34% on a year earlier; public on 29 Apr 2025
Quarter ended 30 Jun 2025: $105.6M, -37% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $89.4M, -36% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $75.1M, -37% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $76.0M, -34% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $76.4M, -28% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $72.0M, -19% on a year earlier; public on 27 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $11.6M, +471% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $3.0M, -35% on a year earlier; public on 3 May 2022
Quarter ended 30 Jun 2022: $2.8M, -63% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $1.8M, -83% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $9.1M, -22% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $2.1M, -30% on a year earlier; public on 2 May 2023
Quarter ended 30 Jun 2023: $1.7M, -39% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $1.7M, -5.1% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $946K, -90% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $1.8M, -13% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $1.9M, +11% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $1.4M, -17% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $2.3M, +142% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $1.5M, -17% on a year earlier; public on 29 Apr 2025
Quarter ended 30 Jun 2025: $1.4M, -29% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $1.4M, -1.9% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $1.4M, -41% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $1.1M, -28% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $969K, -30% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $427K, -69% on a year earlier; public on 27 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 263; public on 14 Feb 2022
31 Mar 2022 report: 264; public on 16 May 2022
30 Jun 2022 report: 266; public on 15 Aug 2022
30 Sep 2022 report: 236; public on 14 Nov 2022
31 Dec 2022 report: 249; public on 14 Feb 2023
31 Mar 2023 report: 249; public on 15 May 2023
30 Jun 2023 report: 212; public on 14 Aug 2023
30 Sep 2023 report: 203; public on 14 Nov 2023
31 Dec 2023 report: 200; public on 14 Feb 2024
31 Mar 2024 report: 174; public on 15 May 2024
30 Jun 2024 report: 148; public on 14 Aug 2024
30 Sep 2024 report: 133; public on 14 Nov 2024
31 Dec 2024 report: 127; public on 14 Feb 2025
31 Mar 2025 report: 121; public on 15 May 2025
30 Jun 2025 report: 115; public on 14 Aug 2025
30 Sep 2025 report: 118; public on 14 Nov 2025
31 Dec 2025 report: 104; public on 17 Feb 2026
31 Mar 2026 report: 108; public on 15 May 2026
30 Jun 2026 report: 109; public on 14 Aug 2026
30 Sep 2026 report: 95; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $1.1M (20 Nov 2026), 31× its normal reading; higher than 98% of its own history.
  • Insider net buying (open market): Insiders bought a net $2.6M in the last 12 months (the 12 months before: $5K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $72.0M in the latest quarter, -19% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 86 insider trades

Last 90 days: 1 sale, $226K; 5 purchases, $1.8M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Nov 2026Parsa KiaiDirectorBuy94,036$12.06$1.1MForm 4
6 Nov 2026Parsa KiaiDirectorBuy661$13.03$9KForm 4
30 Oct 2026Parsa KiaiDirectorBuy5,557$12.24$68KForm 4
30 Sep 2026Daniel R ChardDirectorSellplanned in advance (10b5-1)19,089$11.86$226KForm 4
28 Aug 2026Parsa KiaiDirectorBuy43,150$12.26$529KForm 4
26 Aug 2026Parsa KiaiDirectorBuy4,329$12.00$52KForm 4
21 Aug 2026Parsa KiaiDirectorBuy72,487$11.62$843KForm 4
12 May 2026Scott SchlackmanDirectorBuy5,000$12.59$63KForm 4

95 institutions reported shares at the end of Q3 2026, 70% of the shares outstanding; 13 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Renaissance Technologies LLC859K7.68%$9.9M+80K+10%
Steamboat Capital Partners, LLC846K7.56%$9.7M+139K+20%
BlackRock, Inc.513K4.59%$5.9M+144K+39%
Two Sigma Investments, LP493K4.41%$5.7M+11K+2.3%
Vanguard Capital Management LLC447K3.99%$5.1MNo change
American Century Companies Inc439K3.93%$5.1M+120K+38%
Dimensional Fund Advisors LP373K3.34%$4.3M+10K+2.8%
Marshall Wace, LLP353K3.15%$4.1M+111K+46%
Morgan Stanley244K2.18%$2.8M-48K-16%
Peapod Lane Capital LLC208K1.86%$2.4M-15K-6.8%

Company events

All 31 company events

In 12 months: 4 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Jun 2026Director or officer change8-K
26 May 2026Director or officer changeSame filing: shareholder vote results8-K
20 Mar 2026Director or officer change; Signed a major agreement8-K
5 Jan 2026Director or officer change8-K
20 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
4 Nov 2024A major agreement ended8-K
21 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
20 Apr 2023Director or officer change8-K

The 5 newest of 121 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Jan 2019confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Medifast (MED): reported revenue of $139.2M for the quarter ended 30 Sep 2018, 1.8× the same quarter last year, while it had 1.9M shares sold short in the 31 Jan 2019 report, 6.9× the same report last year. Two unrelated kinds of activity within 126 days.

  • Financials: Quarterly revenue change, became public on 1 Jan 2019
  • Short interest and volume: Short interest spike, became public on 11 Jan 2019
  • Short interest and volume: Short interest spike, became public on 26 Jan 2019
  • Short interest and volume: Short interest spike, became public on 12 Feb 2019
  • Financials: Quarterly revenue change, became public on 5 Mar 2019
  • Short interest and volume: Short interest spike, became public on 28 Feb 2019
  • Short interest and volume: Short interest spike, became public on 12 Mar 2019
  • Short interest and volume: Short interest spike, became public on 27 Mar 2019
  • Short interest and volume: Short interest spike, became public on 10 Apr 2019
  • Financials: Quarterly revenue change, became public on 7 May 2019
2016-09-30: $68.6M2016-12-31: $62.5M2017-03-31: $70.6M2017-06-30: $75.7M2017-09-30: $77.2M2017-12-31: $78.0M2018-03-31: $98.6M2018-06-30: $117.3M2018-09-30: $139.2M
The quarter ended 30 Sep 2018 against the 8 quarters before it. this quarterearliernormal: $76.5M
See the evidence (10 changes)

Financials: Quarterly revenue change became public on 1 Jan 2019

Medifast reported revenue of $139.2M for the quarter ended 30 Sep 2018, 1.8× the same quarter last year.

This period
$139.2M (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
$76.5M
Typical spread (median absolute deviation)
$6.9M
How far from its usual level
+6.2
Same quarter last year
$77.2M
History used
3,014 days
2016-09-30: $68.6M2016-12-31: $62.5M2017-03-31: $70.6M2017-06-30: $75.7M2017-09-30: $77.2M2017-12-31: $78.0M2018-03-31: $98.6M2018-06-30: $117.3M2018-09-30: $139.2M
the quarter ended 30 Sep 20188 earlier quartersnormal: $76.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 11 Jan 2019

Medifast had 1.4M shares sold short in the 31 Dec 2018 report, 4.4× the same report last year.

This period
1.4M (the 31 Dec 2018 report)
Normal report (median of 20 earlier)
458K
Typical spread (median absolute deviation)
149K
How far from its usual level
+4.3
Same report last year
318K
History used
367 days
2017-12-29: 318K2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M
the 31 Dec 2018 report20 earlier reportsnormal: 458K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jan 2019

Medifast had 1.9M shares sold short in the 15 Jan 2019 report, 6.2× the same report last year.

This period
1.9M (the 15 Jan 2019 report)
Normal report (median of 21 earlier)
466K
Typical spread (median absolute deviation)
166K
How far from its usual level
+5.6
Same report last year
300K
History used
382 days
2017-12-29: 318K2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M
the 15 Jan 2019 report21 earlier reportsnormal: 466K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Feb 2019

Medifast had 1.9M shares sold short in the 31 Jan 2019 report, 6.9× the same report last year.

This period
1.9M (the 31 Jan 2019 report)
Normal report (median of 22 earlier)
467K
Typical spread (median absolute deviation)
170K
How far from its usual level
+5.7
Same report last year
275K
History used
398 days
2017-12-29: 318K2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M2019-01-31: 1.9M
the 31 Jan 2019 report22 earlier reportsnormal: 467K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 5 Mar 2019

Medifast reported revenue of $145.8M for the quarter ended 31 Dec 2018, 1.9× the same quarter last year.

This period
$145.8M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$77.6M
Typical spread (median absolute deviation)
$11.1M
How far from its usual level
+4.2
Same quarter last year
$78.0M
History used
3,106 days
2016-12-31: $62.5M2017-03-31: $70.6M2017-06-30: $75.7M2017-09-30: $77.2M2017-12-31: $78.0M2018-03-31: $98.6M2018-06-30: $117.3M2018-09-30: $139.2M2018-12-31: $145.8M
the quarter ended 31 Dec 20188 earlier quartersnormal: $77.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 28 Feb 2019

Medifast had 1.7M shares sold short in the 15 Feb 2019 report, 7.1× the same report last year.

This period
1.7M (the 15 Feb 2019 report)
Normal report (median of 23 earlier)
467K
Typical spread (median absolute deviation)
173K
How far from its usual level
+4.9
Same report last year
243K
History used
413 days
2017-12-29: 318K2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M2019-01-31: 1.9M2019-02-15: 1.7M
the 15 Feb 2019 report23 earlier reportsnormal: 467K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Mar 2019

Medifast had 1.8M shares sold short in the 28 Feb 2019 report, 7.6× the same report last year.

This period
1.8M (the 28 Feb 2019 report)
Normal report (median of 24 earlier)
485K
Typical spread (median absolute deviation)
198K
How far from its usual level
+4.6
Same report last year
239K
History used
426 days
2017-12-29: 318K2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M2019-01-31: 1.9M2019-02-15: 1.7M2019-02-28: 1.8M
the 28 Feb 2019 report24 earlier reportsnormal: 485K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Mar 2019

Medifast had 2.0M shares sold short in the 15 Mar 2019 report, 6.3× the same report last year.

This period
2.0M (the 15 Mar 2019 report)
Normal report (median of 24 earlier)
510K
Typical spread (median absolute deviation)
233K
How far from its usual level
+4.4
Same report last year
322K
History used
441 days
2018-01-12: 300K2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M2019-01-31: 1.9M2019-02-15: 1.7M2019-02-28: 1.8M2019-03-15: 2.0M
the 15 Mar 2019 report24 earlier reportsnormal: 510K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Apr 2019

Medifast had 2.0M shares sold short in the 29 Mar 2019 report, 6.2× the same report last year.

This period
2.0M (the 29 Mar 2019 report)
Normal report (median of 24 earlier)
579K
Typical spread (median absolute deviation)
246K
How far from its usual level
+3.9
Same report last year
322K
History used
455 days
2018-01-31: 275K2018-02-15: 243K2018-02-28: 239K2018-03-15: 322K2018-05-15: 517K2018-06-15: 503K2018-06-29: 467K2018-07-13: 466K2018-07-31: 450K2018-08-15: 333K2018-08-31: 397K2018-09-14: 419K2018-09-28: 754K2018-10-15: 740K2018-10-31: 753K2018-11-15: 641K2018-11-30: 825K2018-12-14: 1.1M2018-12-31: 1.4M2019-01-15: 1.9M2019-01-31: 1.9M2019-02-15: 1.7M2019-02-28: 1.8M2019-03-15: 2.0M2019-03-29: 2.0M
the 29 Mar 2019 report24 earlier reportsnormal: 579K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 7 May 2019

Medifast reported revenue of $165.9M for the quarter ended 31 Mar 2019, 1.7× the same quarter last year.

This period
$165.9M (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
$88.3M
Typical spread (median absolute deviation)
$15.1M
How far from its usual level
+3.5
Same quarter last year
$98.6M
History used
3,196 days
2017-03-31: $70.6M2017-06-30: $75.7M2017-09-30: $77.2M2017-12-31: $78.0M2018-03-31: $98.6M2018-06-30: $117.3M2018-09-30: $139.2M2018-12-31: $145.8M2019-03-31: $165.9M
the quarter ended 31 Mar 20198 earlier quartersnormal: $88.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 20 Nov 2026Insiders record

    Kiai Parsa (director) bought 94,036 shares of MED ($1.1M)

  2. 6 Nov 2026Insiders record

    Kiai Parsa (director) bought 661 shares of MED ($8,610)

  3. 30 Oct 2026Insiders record

    Kiai Parsa (director) bought 5,557 shares of MED ($68,027)

  4. 29 Aug 2026Insiders record

    Kiai Parsa (director) bought 43,150 shares of MED ($529,019) (dated 28 Aug 2026)

  5. 27 Aug 2026Insiders record

    Kiai Parsa (director) bought 4,329 shares of MED ($51,948) (dated 26 Aug 2026)

  6. 22 Aug 2026Insiders record

    Kiai Parsa (director) bought 72,487 shares of MED ($842,609) (dated 21 Aug 2026)

  7. 1 Jun 2026Filings record

    Director or officer change

  8. 26 May 2026Filings record

    Director or officer change

  9. 13 May 2026Insiders record

    SCHLACKMAN SCOTT (director) bought 5,000 shares of MED ($62,950) (dated 12 May 2026)

  10. 28 Mar 2026Insiders record

    Chard Daniel R (Chairman & CEO) bought 17,678 shares of MED ($178,725) (dated 27 Mar 2026)

  11. 20 Mar 2026Filings record

    Director or officer change

  12. 5 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 5 Jan 2026Filings record

    Director or officer change

  14. 20 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 20 Jun 2025Filings record

    Director or officer change

  16. 18 Jun 2025Insiders record

    Chard Daniel R (Chairman & CEO) bought 381 shares of MED ($5,003) (dated 17 Jun 2025)

  17. 4 Nov 2024Filings record

    A major agreement ended

  18. 25 Jul 2024Short interest and volume change

    had 3.0M shares sold short in the 15 Jul 2024 report, 2.0× the same report last year.

    Same report last year: 1.5M; its normal report is 1.8M.

    See the evidence
    This period
    3.0M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    168K
    How far from its usual level
    +4.6
    Same report last year
    1.5M
    History used
    2,390 days
    2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M2024-05-15: 3.2M2024-05-31: 3.4M2024-06-14: 3.5M2024-06-28: 2.9M2024-07-15: 3.0M
    the 15 Jul 2024 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 11 Jul 2024Short interest and volume change

    had 2.9M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year.

    Same report last year: 1.6M; its normal report is 1.8M.

    See the evidence
    This period
    2.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    155K
    How far from its usual level
    +5.0
    Same report last year
    1.6M
    History used
    2,373 days
    2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M2024-05-15: 3.2M2024-05-31: 3.4M2024-06-14: 3.5M2024-06-28: 2.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 27 Jun 2024Short interest and volume change

    had 3.5M shares sold short in the 14 Jun 2024 report, 2.2× the same report last year.

    Same report last year: 1.6M; its normal report is 1.8M.

    See the evidence
    This period
    3.5M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    155K
    How far from its usual level
    +7.3
    Same report last year
    1.6M
    History used
    2,359 days
    2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M2024-05-15: 3.2M2024-05-31: 3.4M2024-06-14: 3.5M
    the 14 Jun 2024 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 21 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 21 Jun 2024Filings record

    Director or officer change

  23. 12 Jun 2024Short interest and volume change

    had 3.4M shares sold short in the 31 May 2024 report, 2.2× the same report last year.

    Same report last year: 1.5M; its normal report is 1.7M.

    See the evidence
    This period
    3.4M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    165K
    How far from its usual level
    +6.9
    Same report last year
    1.5M
    History used
    2,345 days
    2023-05-31: 1.5M2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M2024-05-15: 3.2M2024-05-31: 3.4M
    the 31 May 2024 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 May 2024Short interest and volume change

    had 3.2M shares sold short in the 15 May 2024 report, 2.0× the same report last year.

    Same report last year: 1.6M; its normal report is 1.7M.

    See the evidence
    This period
    3.2M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +6.6
    Same report last year
    1.6M
    History used
    2,329 days
    2023-05-15: 1.6M2023-05-31: 1.5M2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M2024-05-15: 3.2M
    the 15 May 2024 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 May 2024Short interest and volume change

    had 3.1M shares sold short in the 30 Apr 2024 report, 1.8× the same report last year.

    Same report last year: 1.7M; its normal report is 1.7M.

    See the evidence
    This period
    3.1M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    124K
    How far from its usual level
    +7.5
    Same report last year
    1.7M
    History used
    2,314 days
    2023-04-28: 1.7M2023-05-15: 1.6M2023-05-31: 1.5M2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M2024-04-30: 3.1M
    the 30 Apr 2024 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 Apr 2024Short interest and volume change

    had 3.0M shares sold short in the 15 Apr 2024 report, 1.9× the same report last year.

    Same report last year: 1.6M; its normal report is 1.7M.

    See the evidence
    This period
    3.0M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    122K
    How far from its usual level
    +7.0
    Same report last year
    1.6M
    History used
    2,299 days
    2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.6M2023-05-31: 1.5M2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M2024-04-15: 3.0M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 10 Apr 2024Short interest and volume change

    had 2.7M shares sold short in the 28 Mar 2024 report, 1.7× the same report last year.

    Same report last year: 1.5M; its normal report is 1.7M.

    See the evidence
    This period
    2.7M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    119K
    How far from its usual level
    +5.4
    Same report last year
    1.5M
    History used
    2,281 days
    2023-03-31: 1.5M2023-04-14: 1.6M2023-04-28: 1.7M2023-05-15: 1.6M2023-05-31: 1.5M2023-06-15: 1.6M2023-06-30: 1.6M2023-07-14: 1.5M2023-07-31: 1.5M2023-08-15: 1.5M2023-08-31: 1.6M2023-09-15: 1.7M2023-09-29: 1.8M2023-10-13: 1.7M2023-10-31: 1.7M2023-11-15: 1.7M2023-11-30: 1.8M2023-12-15: 1.8M2023-12-29: 1.7M2024-01-12: 1.8M2024-01-31: 1.9M2024-02-15: 1.9M2024-02-29: 1.9M2024-03-15: 2.0M2024-03-28: 2.7M
    the 28 Mar 2024 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Nov 2023Insiders record

    Thomas Andrea B (director) bought 50 shares of MED ($3,471) (dated 9 Nov 2023)

  29. 10 Nov 2023Insiders record

    SCHLACKMAN SCOTT (director) bought 53 shares of MED ($3,627) (dated 9 Nov 2023)

  30. 10 Nov 2023Insiders record

    Hoer Michael A. (director) bought 50 shares of MED ($3,428) (dated 9 Nov 2023)

  31. 10 Nov 2023Insiders record

    BROWN JEFFREY J (director) bought 155 shares of MED ($10,845) (dated 9 Nov 2023)

  32. 7 Nov 2023Financials change

    reported revenue of $235.9M for the quarter ended 30 Sep 2023, 40% below the same quarter last year.

    Same quarter last year: $390.4M; its normal quarter is $392.3M.

    See the evidence
    This period
    $235.9M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $392.3M
    Typical spread (median absolute deviation)
    $34.3M
    How far from its usual level
    -3.1
    Same quarter last year
    $390.4M
    History used
    4,840 days
    2021-03-31: $340.7M2021-06-30: $394.2M2021-09-30: $413.4M2022-03-31: $417.6M2022-06-30: $453.3M2022-09-30: $390.4M2023-03-31: $349.0M2023-06-30: $296.2M2023-09-30: $235.9M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $392.3M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 11 Aug 2023Insiders record

    Thomas Andrea B (director) bought 38 shares of MED ($3,409) (dated 10 Aug 2023)

  34. 11 Aug 2023Insiders record

    BROWN JEFFREY J (director) bought 733 shares of MED ($72,857) (dated 10 Aug 2023)

  35. 11 Aug 2023Insiders record

    Hoer Michael A. (director) bought 38 shares of MED ($3,366) (dated 10 Aug 2023)

  36. 11 Aug 2023Insiders record

    SCHLACKMAN SCOTT (director) bought 40 shares of MED ($3,561) (dated 10 Aug 2023)

  37. 12 May 2023Insiders record

    BROWN JEFFREY J (director) bought 769 shares of MED ($68,978) (dated 11 May 2023)

  38. 12 May 2023Insiders record

    Thomas Andrea B (director) bought 13 shares of MED ($1,133) (dated 11 May 2023)

  39. 12 May 2023Insiders record

    HALLQUIST CONSTANCE J. (director) bought 13 shares of MED ($1,167) (dated 11 May 2023)

  40. 12 May 2023Insiders record

    SCHLACKMAN SCOTT (director) bought 13 shares of MED ($1,151) (dated 11 May 2023)

Showing the newest 40 of 130 entries; narrow the window or the kind of data to see older ones.

Not listed: 166 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000910329
Ticker
MED
Domain
medifastinc.com
Employer name
Jason Pharmaceuticals, Inc. (1 unverified)
Fein
52-1237423 (1 unverified)
Hq location
MD|BALTIMORE|21224 (1 unverified)
Name
Corporate Subsidiaries, HEALTHRITE INC, Jason Enterprises, Inc, Jason Pharmaceuticals, Inc and 5 more
Wikidata
Q6806861
Wikipedia
Medifast
  • DOL H-1B labor condition applications and PERM certifications12 data points2 Feb 2026 to 10 Aug 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)157 records19 Jan 2016 to 26 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1193 data points31 Dec 2008 to 19 Oct 2026
  • SEC Form 4 insider transactions86 records, 244 data points6 Jan 2016 to 20 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026